REFERENCES
1. Bareschino MA, Schettino C, Rossi A, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3:122-33.
2. Cufer T, Ovcaricek T, O'Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer. 2013;49:1216-25.
3. Boccellino M, Pinto F, Ieluzzi V, et al. Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates. J Cell Physiol. 2019;234:23798-806.
4. Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive Summary of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7:295-301.
5. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
6. Gasparri R, Sabalic A, Spaggiari L. The early diagnosis of lung cancer: critical gaps in the discovery of biomarkers. J Clin Med. 2023;12:7244.
7. O'Sullivan B, Brierley J, Byrd D, et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol. 2017;18:849-51.
8. Hofman V, Ilie M, Long E, et al. Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls. Curr Mol Med. 2014;14:440-56.
10. Jiang SS, Deng B, Feng YG, et al. Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review. BMC Pulm Med. 2019;19:262.
11. Qian H, Zhang Y, Xu J, He J, Gao W. Progress and application of circulating tumor cells in non-small cell lung cancer. Mol Ther Oncolytics. 2021;22:72-84.
12. Wan JW, Gao MZ, Hu RJ, et al. A preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancer. Ann Transl Med. 2015;3:352.
13. Leroy S, Benzaquen J, Mazzetta A, et al. Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France. BMJ Open. 2017;7:e018884.
14. Sun M, Lu D, Li X, et al. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer. Cancer Med. 2024;13:e70216.
15. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275-92.
16. Yang MH, Imrali A, Heeschen C. Circulating cancer stem cells: the importance to select. Chin J Cancer Res. 2015;27:437-49.
17. Jiang ZF, Wang M, Xu JL. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci. 2018;194:1-6.
18. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147:992-1009.
19. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479-91.
20. Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11:858-73.
21. Lozar T, Gersak K, Cemazar M, Kuhar CG, Jesenko T. The biology and clinical potential of circulating tumor cells. Radiol Oncol. 2024;58:458.
22. Lawrence R, Watters M, Davies CR, Pantel K, Lu YJ. Circulating tumour cells for early detection of clinically relevant cancer. Nat Rev Clin Oncol. 2023;20:487-500.
23. Brozos-Vázquez EM, Díaz-Peña R, García-González J, et al. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. Cancer Immunol Immunother. 2021;70:1177-88.
24. Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2:351-65.
25. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011;129:1651-60.
26. Ilie M, Hofman V, Long-Mira E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med. 2014;2:107.
27. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009;15:6980-6.
28. Dirix L, Buys A, Oeyen S, et al. Circulating tumor cell detection: a prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer. Breast Cancer Res Treat. 2022;193:437-44.
29. Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer. 2011;105:847-53.
30. Hillig T, Horn P, Nygaard AB, et al. In vitro detection of circulating tumor cells compared by the CytoTrack and CellSearch methods. Tumour Biol. 2015;36:4597-601.
31. Huang C, Ding S, Huang C, et al. Distribution and clinical analysis of EpCAM+/Vimentin+ circulating tumor cells in high-risk population and cancer patients. Front Oncol. 2021;11:642971.
32. Lindgren G, Wennerberg J, Ekblad L. Cell line dependent expression of EpCAM influences the detection of circulating tumor cells with CellSearch. Laryngoscope Investig Otolaryngol. 2017;2:194-8.
33. Rossi D, Dannhauser D, Nastri BM, et al. New trends in precision medicine: a pilot study of pure light scattering analysis as a useful tool for non-small cell lung cancer (NSCLC) diagnosis. J Pers Med. 2021;11:1023.
34. Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19:553-67.
35. Fiorelli A, Accardo M, Carelli E, Angioletti D, Santini M, Di Domenico M. Circulating tumor cells in diagnosing lung cancer: clinical and morphologic analysis. Ann Thorac Surg. 2015;99:1899-905.
36. Wang X, Bai L, Kong L, Guo Z. Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer. Front Oncol. 2024;14:1411731.
37. Saini VM, Oner E, Ward MP, et al. A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer. Mol Oncol. 2025;19:2014-37.
38. Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. 2015;12:511-26.
39. He S, Liu P, Wu Y, et al. Combining rVAR2 and anti-EpCAM to increase the capture efficiency of non-small-cell lung cancer cell lines in the flow enrichment target capture Halbach (FETCH) magnetic separation system. Int J Mol Sci. 2024;25:9816.
40. Salanti A, Clausen TM, Agerbæk MØ, et al. Targeting human cancer by a glycosaminoglycan binding malaria protein. Cancer Cell. 2015;28:500-14.
41. Sun Z, Li P, Wu Z, et al. Circulating CD45+EpCAM+ cells as a diagnostic marker for early-stage primary lung cancer. Front Med Technol. 2022;4:982308.
42. Zhang Y, Men Y, Wang J, et al. Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC. J Cancer Res Clin Oncol. 2022;148:1137-46.
43. Zhang Z, Shiratsuchi H, Lin J, et al. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014;5:12383-97.
44. Ye T, Shi H, Phan-Thien N, Lim CT, Li Y. Numerical design of a microfluidic chip for probing mechanical properties of cells. J Biomech. 2019;84:103-12.
45. Deng Z, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022;83:104237.
46. Abramson Cancer Center at Penn Medicine. The utility of circulating tumor cells as confirmation of pathologic diagnosis in patients with suspected early stage non-small cell lung cancer. 2020. Available from: https://clinicaltrials.gov/study/NCT02380196 [Last accessed on 29 Jul 2025].
47. Jin XR, Zhu LY, Qian K, et al. Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review. Oncotarget. 2017;8:23130-41.
48. Markou AN, Londra D, Stergiopoulou D, et al. Preoperative mutational analysis of circulating tumor cells (CTCs) and plasma-cfDNA provides complementary information for early prediction of relapse: a pilot study in early-stage non-small cell lung cancer. Cancers. 2023;15:1877.
49. Wang HM, Zhang CY, Peng KC, et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study. Cell Rep Med. 2023;4:100911.
50. Pérez-Cabello JA, Artero-Castro A, Molina-Pinelo S. Small cell lung cancer unveiled: exploring the untapped resource of circulating tumor cells-derived organoids. Crit Rev Oncol Hematol. 2025;207:104622.
51. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345:1247125.
52. Huang L, Xu Y, Wang N, et al. Next-generation preclinical functional testing models in cancer precision medicine: CTC-derived organoids. Small Methods. 2024;8:e2301009.
53. Lin S, Huang G, Cheng L, et al. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. mAbs. 2018;10:1301-11.
54. Lahmadi M. 5P Circulating tumor cell-derived organoids from lung adenocarcinoma patients for assessment of EGFR and KRAS mutations. Ann Oncol. 2024;35:S216.
55. O'byrne KJ, Kapeleris J, Kulasinghe A, et al. Culture of circulating tumour cells derived from non-small cell lung cancer. JCO. 2020;38:e21692.
56. De Renzi G, de Marco G, de Meo M, Del Rosso E, Gazzaniga P, Nicolazzo C. In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity. Cancer Drug Resist. 2022;5:245-60.
